文献速递临床试验与 GCP基础与转化研究

一项多中心、患者与评估者盲法、非劣效性、随机对照II期试验:比较肾移植术后第一年标准免疫抑制与指环病毒TTV引导的免疫抑制(TTVguideIT)

A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT.
PubMed 文献 · Trials · 2023-03-22

TTVguideIT是一项多中心、患者与评估者盲法、非劣效性、随机对照II期试验,计划在6个欧洲国家13个学术中心招募260例低免疫风险成人肾移植受者,随机按1:1接受TTV载量引导或当地中心标准他克莫司免疫抑制9个月,主要复合终点为感染、活检证实的移植物排斥、移植物丢失或死亡。

要点

  • TTV载量引导免疫抑制拟用于肾移植术后第3个月后仍存在TTV感染的低免疫风险受者。
  • 主要复合终点包括感染、活检证实的移植物排斥、移植物丢失或死亡。
  • 首例入组日期为2022年8月,计划结束日期为2025年4月。

核心结论

  • 该试验旨在证明TTV引导免疫抑制的安全性、耐受性和初步疗效,并可能为TTV引导免疫抑制提供原理验证。

研究设计与样本

  • 多中心、随机、对照、干预性、两臂、非劣效性、患者与评估者盲法、研究者驱动的II期试验。
  • 计划在6个欧洲国家的13个学术中心招募260例稳定、低免疫风险、接受以他克莫司为基础免疫抑制且移植术后第3个月后存在TTV感染的成人肾移植受者。
  • 受者按1:1比例随机(分配隐藏)接受TTV载量引导的他克莫司或当地中心标准他克莫司治疗9个月。

关键数值与推荐

  • 主要复合终点包括感染、活检证实的移植物排斥、移植物丢失或死亡。
  • 主要次要终点包括估算肾小球滤过率、移植术后第12个月方案活检检测到的移植物排斥(包括分子显微镜)、新发供者特异性抗体、健康相关生活质量和药物依从性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunosuppression after kidney transplantation is mainly guided via plasma tacrolimus trough level, which cannot sufficiently predict allograft rejection and infection. The plasma load of the non-pathogenic and highly prevalent torque teno virus (TTV) is associated with the immunosuppression of its host. Non-interventional studies suggest the use of TTV load to predict allograft rejection and infection. The primary objective of the current trial is to demonstrate the safety, tolerability and preliminary efficacy of TTV-guided immunosuppression. METHODS: For this purpose, a randomised, controlled, interventional, two-arm, non-inferiority, patient- and assessor-blinded, investigator-driven phase II trial was designed. A total of 260 stable, low-immunological-risk adult recipients of a kidney graft with tacrolimus-based immunosuppression and TTV infection after month 3 post-transplantation will be recruited in 13 academic centres in six European countries. Subjects will be randomised in a 1:1 ratio (allocation concealment) to receive tacrolimus either guided by TTV load or according to the local centre standard for 9 months. The primary composite endpoint includes the occurrence of infections, biopsy-proven allograft rejection, graft loss, or death. The main secondary endpoints include estimated glomerular filtration rate, graft rejection detected by protocol biopsy at month 12 post-transplantation (including molecular microscopy), development of de novo donor-specific antibodies, health-related quality of life, and drug adherence. In parallel, a comprehensive biobank will be established including plasma, serum, urine and whole blood. The date of the first enrolment was August 2022 and the planned end is April 2025. DISCUSSION: The assessment of individual kidney transplant recipient immune function might enable clinicians to personalise immunosuppression, thereby reducing infection and rejection. Moreover, the trial might act as a proof of principle for TTV-guided immunosuppression and thus pave the way for broader clinical applications, including as guidance for immune modulators or disease-modifying agents. TRIAL REGISTRATION: EU CT-Number: 2022-500024-30-00.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Haupenthal F, Rahn J, Maggi F, et al. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT. Trials. 2023. PMID: 36949445. doi:10.1186/s13063-023-07216-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。